Match Context and Document information |
These search terms are highlighted: dea verification
URL: | https://www.deadiversion.usdoj.gov/...info/buprenorphine.pdf |
Depth: | 2 clicks away from Home |
Size: | 155,294 bytes |
Modified: | 2024-05-28 12:27:19 |
Categories: | -None- |
Title: | Buprenorphine |
Description: | -None- |
Keywords: | Buprenex Suboxone Subutex Zubsolv Sublocade Butrans |
Meta data: | -None- |
Body: | Drug Enforcement Administration
Diversion Control Division
Drug & Chemical Evaluation Section
BUPRENORPHINE
(Trade Names: Buprenex®, Suboxone®, Subutex®,
Zubsolv®, Sublocade®, Butrans®)
May 2022
Introduction:
Buprenorphine is a schedule III narcotic analgesic. It was first
marketed in the United States in 1985 as a schedule V narcotic
analgesic. Initially, the only available buprenorphine product in the
United States had been a low-dose (0.3 mg/ml) injectable
formulation under the brand name, Buprenex®.
In October 2002, the Food and Drug Administration (FDA)
approved two buprenorphine products (Suboxone® and
Subutex®)
1
for the treatment of narcotic addiction. Both products
are high dose (2 mg and 8 mg) sublingual (under the tongue) tablets.
Suboxone® is a combination product with buprenorphine and
naloxone in a 4:1 ratio, respectively. After reviewing the available
data and receiving a schedule III recommendation from the
Department of Health and Human Services (HHS), DEA placed
buprenorphine and all products containing buprenorphine into
schedule III in 2002. Since 2003, diversion, trafficking and abuse of
buprenorphine have become more common in the United States.
Diversion, trafficking, and abuse of other buprenorphine products
have occurred in Europe and other areas of the world. Between
2010 and 2017, FDA has approved additional buprenorphine
formulations: Butrans® (extended release transdermal film
containing buprenorphine), Zubsolv® (buprenorphine/naloxone
sublingual tablets), and Sublocade® (buprenorphine extended-
release injection).
Licit Uses:
Buprenorphine is intended for the treatment of pain
(Buprenex®) and opioid addiction (Suboxone®, Zubsolv®, and
Sublocade®). In 2001, 2005, and 2006, the Narcotic Addict
Treatment Act was amended to allow qualified physicians, under
certification of HHS, to prescribe schedule III-V narcotic drugs (FDA
approved for the indication of narcotic treatment) for opioid
addiction, up to 30 patients per physician at any time, outside the
context of clinic-based narcotic treatment programs (Pub. L. 106-
310). This limit was increased to 100 patients per physician, who
meet the specified criteria, under the Office of National Drug Control
Policy Reauthorization Act (P.L. 69-469, ONDCPRA), which
became effective on December 29, 2006.
Since then, guidelines have been updated to allow physicians,
physician assistants, nurse practitioners, clinical nurse specialists,
certified registered nurse anesthetists, and certified nurse midwives
to treat up to 30 patients at any one time with opioid use disorder
using buprenorphine without having to make certain training related
certifications (86 FR 22439). Qualified practitioners who undertake
the required training may treat up to 100 patients using
buprenorphine for the treatment of opioid use disorder. After one
year at the 100- patient limit, qualifying practitioners may increase
their patient limit to 275.
IQVIA
TM
National Prescription Audit Plus indicates that since
2002, 171 million buprenorphine prescriptions have been dispensed
in the United States. Of these 171 million, almost 138 million
prescriptions (80.2%) were buprenorphine and naloxone
combination products (data as of May 24, 2022).
Chemistry and Pharmacology:
Buprenorphine is an opioid receptor partial agonist. It produces
the effects typical of both classic mu opioid receptor agonists (e.g.,
morphine) and partial agonists (e.g., pentazocine) depending on
dose, pattern of use, and population taking the drug. It is about 20-
30 times more potent than morphine as an analgesic; and like
morphine it produces dose-related euphoria, drug liking, papillary
1
Subutex® has been discontinued by the manufacturer.
constriction, respiratory depression, and sedation. However, acute,
high doses of buprenorphine have been shown to have a blunting
effect on both physiological and psychological effects due to its
partial opioid activity.
Buprenorphine is a long-acting (24-72 hours) opioid that
produces less respiratory depression at high doses than other
narcotic drugs. However, severe respiratory depression can occur
when buprenorphine is combined with other central nervous system
depressants, especially benzodiazepines. Deaths have resulted
from this combination.
The addition of naloxone in combination products (Suboxone®
and Zubsolv®) is intended to block the euphoric high resulting from
the injection of this drug by non-buprenorphine maintained narcotic
abusers.
Illicit Uses:
Like other opioids commonly abused, buprenorphine is capable
of producing significant euphoria. Data from the United States and
other countries indicate that buprenorphine has been abused by
various routes of administration (sublingual, intranasal, and
injection) and has gained popularity as a heroin substitute and as a
primary drug of abuse. Large percentages of the drug abusing
populations in some areas of France, Ireland, Scotland, India,
Nepal, Bangladesh, Pakistan, and New Zealand have reported
abusing buprenorphine by injection and in combination with a
benzodiazepine.
Illicit Distribution:
The National Forensic Laboratory Information System (NFLIS-
Drug) is a DEA database that collects scientifically verified data on
drug items and cases submitted to and analyzed by Federal, state,
and local forensic laboratories. Between 1997 and 2002, there were
42 reports of buprenorphine to NFLIS-Drug. From 2002 to present,
there have been 207,088 reports of buprenorphine to NFLIS-Drug,
with the highest number of annual reports occurring in 2019 with
21,255 reports (queried May 24, 2022).
According to the Substance Abuse and Mental Health Services
Administration's (SAMHSA) Treatment Episode Data Set (TEDS)
2019, there were an estimated 8,522 admissions of persons 12 and
older to publicly funded substance use treatment centers for
buprenorphine use. Of these 8,522 admissions, buprenorphine was
the primary drug of abuse in 3,694 (43%) admissions.
According to the 2020 Annual Report of the American
Association of Poison Control Centers' National Poison Data
System (NPDS): 38
th
Annual report, U.S. poison centers recorded
4,958 case mentions with buprenorphine, 2,948 single substance
exposure cases, and two deaths involving toxic exposure from
buprenorphine in 2020.
User Population:
In countries where buprenorphine has gained popularity as a
drug of abuse, it is sought by a wide variety of narcotic abusers:
young naïve individuals, non-addicted opioid abusers, heroin
addicts and buprenorphine treatment clients.
Control Status:
Buprenorphine and all products containing buprenorphine are
controlled in schedule III of the Controlled Substances Act.
Comments and additional information are welcomed by the Drug and Chemical Evaluation
Section; Fax 571-362-4250, Telephone 571-362-3249, or Email DPE@dea.gov.
|
|